Fig. 1

Detection of EGFR and HER-2 proteins in endometrial adenocarcinoma (surgically resected endometrioid cancer sample). a We used tissue samples of well differentiated (G1), moderately differentiated (G2), and poorly differentiated (G3) endometrial carcinoma for immunohistochemical study. The tissues were fixed in formalin and embedded in paraffin. Sections were taken from the paraffin-embedded tissue and stained with 1:200 anti-EGFR or 1:150 anti-HER-2. Primary antibody binding was detected through a biotin-conjugated secondary antibody. Top panels, HE stained; upper middle panels, stained with anti-EGFR; lower middle panels, stained with anti-HER-2; bottom panels, negative control. Magnification × 200. ars =1000 μm. b The expression status of EGFR and HER-2 in each grade of tumor were assessed by immunohistochemistry. The ratio of immunopositive cases for each protein is represented in the bars graph. c The carcinoma portions were excised, and RNA was isolated. EGFR and HER-2 mRNA levels were measured using quantitative RT-PCR. GAPDH mRNA levels were quantitated as an internal control. The amounts of EGFR and HER-2 mRNA were respectively normalized by the amounts of GAPDH mRNA. *, Decrease in the expression level of EGFR mRNA in G3 compared to those in G1 and G2 cancers, P < 0.05